AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

XTL Biopharmaceuticals Ltd.

Regulatory Filings Jan 3, 2006

7116_rns_2006-01-03_bed64d1a-5a47-4731-8bad-894881a36633.htm

Regulatory Filings

Open in Viewer

Opens in native device viewer

C004 ��� �� �� ������������� ��"� 2
Public X T L BIOPHARMACEUTICALS LTD
4312 Corporation no: 520039470
Stock Exchange/Market: ��� �� ��
1996
352 Hasapir 3 , Nes Ziona 76100 , ,
Tel: 08-9304444 , Fax: 08-9304445
E.mail address: [email protected] Date of transmission: 03/01/2006
Time of broadcast: 09:46 09:45:55
Reference: 2006-02-003012
Israel Securities Authority Tel Aviv Stock Exchange
www.isa.gov.il www.tase.co.il

Immediate report on other matterDon't use this form if there is more adequate one

XTL Biopharmaceuticals Announces Appointment of Ron Bentsur as Chief Executive Officer
Attached file 27-05Appointment_of_Ron_Bentsur_as_CEO_3Jan05_isa.pdf
References of previous documents relating to this matter(the reference does not constitute incorporation by reference):
Previous names of reporting entity: XENOGRAFT TECHNOLOGIES LTD
Date of revision of form structure: 28/12/2005
- - -
Name of the Signatory : Burgin Jonathan , , Position of Signatory in the reporting corporation: Chief Financial Officer
Hasapir Telephone: 08-9304440 , Facsimile: 08-9300659 , E-mail: [email protected]

Talk to a Data Expert

Have a question? We'll get back to you promptly.